Published in Cancer Weekly, October 25th, 2005
Troxatyl is currently in a pivotal phase II/III clinical trial for the third-line treatment of AML. The company announced earlier in May that the U.S. Food & Drug Administration had granted Troxatyl orphan drug designation in the U.S. for the treatment of AML.
The EMEA orphan drug designation provides incentives to companies that develop drugs for diseases affecting no more than 50 in 100,000 persons in the European Union...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.